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ABSTRACT: Six morpholine-(iso)thiosemicarbazone hy-
brids HL1−HL6 and their Cu(II) complexes with good-to-
moderate solubility and stability in water were synthesized
and characterized. Cu(II) complexes [Cu(L1−6)Cl] (1−6)
formed weak dimeric associates in the solid state, which did
not remain intact in solution as evidenced by ESI-MS. The
lead proligands and Cu(II) complexes displayed higher
antiproliferative activity in cancer cells than triapine. In
addition, complexes 2−5 were found to speciﬁcally inhibit the
growth of Gram-positive bacteria Staphylococcus aureus with
MIC50 values at 2−5 μg/mL. Insights into the processes
controlling intracellular accumulation and mechanism of
action were investigated for 2 and 5, including the role of ribonucleotide reductase (RNR) inhibition, endoplasmic reticulum
stress induction, and regulation of other cancer signaling pathways. Their ability to moderately inhibit R2 RNR protein in the
presence of dithiothreitol is likely related to Fe chelating properties of the proligands liberated upon reduction.
1. INTRODUCTION
Progress in modern anticancer therapy has led to signiﬁcant
improvements in survival rates of cancer patients. However,
even though more patients achieve remission nowadays, their
lifespan often remains short.1 One of the major causes of
cancer death is the malignant process itself, which is associated
with extensive formation of metastases, but it is not commonly
mentioned that a signiﬁcant number of immunocompromised
cancer patients die due to infections, such as pneumonia and
peritonitis.2 Despite that cancer patients are very prone to
develop infections during chemotherapy, their preventive
antibiotic treatment is hampered by additional adverse eﬀects.3
However, recent clinical evidence demonstrated that beneﬁts
of antibiotic prophylaxis of cancer patients outweighed its
risks.4 The simultaneous suppression of pathogenic micro-
organisms during anticancer chemotherapy could not only
interrupt or abolish tumor growth but also eventually protect
cancer patients from infection. Hence, the development of
novel drugs which exhibit dual anticancer and antibacterial
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properties in comparable concentration range would aﬀect the
malignant process and simultaneously decrease the risk of
patients’ death due to infection, febrile neutropenia, and
bacteraemia.
Both cancer and bacterial cells share similar properties, such
as high rate of proliferation, rapid adjustment, and quick
spreading within the host and aggressive disease progression.5
To sustain such rapid proliferation, cancer and bacterial cells
have to support DNA replication and production of RNA by
increasing de novo nucleotide synthesis. Ribonucleotide
reductase (RNR) is the key enzyme that catalyzes the
reduction of ribonucleotides to their corresponding deoxy-
ribonucleotides, thereby initiating DNA synthesis or repair,
making it an important biomolecular target for drugs with
anticancer and antibacterial properties.6,7 RNR consists of a
large subunit (NrdA or R1), which contains the allosteric site
that regulates and catalyzes substrate reduction, and a small
subunit (NrdB or R2) with the diferric-tyrosyl radical cofactor,
essential for the catalytic activity of the RNR enzyme. Small
molecules, that can sequester Fe from the dinuclear metal
center and/or scavenge the tyrosyl radical, inhibit R2 activity,
thereby preventing de novo DNA synthesis in cancer cells and
bacteria.
α-N-Heterocyclic thiosemicarbazones (TSCs) are excellent
transition-metal chelators and have a broad range of activities,
including anticancer and antibacterial properties, which are
believed to be at least partially due to their RNR inhibition.8
To date, several TSC compounds, namely, 3-amino-2-
pyridinecarboxaldehyde TSC (triapine),9−11 di-2-pyridylke-
tone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC),12,13
and (E)-N′-(6,7-dihydroquinolin-8(5H)-ylidene)-4-(pyridine-
2-yl)piperazine-1-carbothiohydrazide (COTI-2)14 are under-
going phase I and II clinical trials against various types of
cancer. The main caveat in the use of TSCs is their high
toxicity which is reﬂected in a number of side eﬀects in clinical
trials involving triapine.9−11 Many studies have shown that
Cu(II)−TSC complexes often display better selectivity than
their TSC proligands, which can be attributed to the induction
of diﬀerent intracellular signaling pathways.15
Despite advances in the design and synthesis of new TSCs
and Cu(II)−TSC complexes over the years, these compounds
are facing the problem of low aqueous solubility, thereby
hampering their further development. Therefore, the synthesis
of water-soluble and cytotoxic TSCs and Cu(II)−TSC
complexes requires a thoughtful selection of the functional
groups that can be attached at the TSC backbone without
reducing their biological activity.16−20 With the aim to reach
the optimal combination of aqueous solubility and high
cytotoxicity, we designed new (iso)TSC−morpholine hybrids
and their Cu(II) complexes. Notably, morpholine moiety was
chosen because it confers excellent water solubility, which
typically translates into an improved pharmacological eﬀect.
Additionally, morpholine derivatives possess a broad spectrum
of biological activities, including anticancer and antibacterial
therapeutic potential.21 For example, commercial anticancer
drugs aprepitant and geﬁnitib, as well as antibacterial drugs
ﬁnaﬂoxacin and levoﬂoxacin include a morpholine fragment in
their structures.
Herein, we report on the synthesis of water-soluble
proligands HL1−6 and Cu(II) complexes 1−6 (Chart 1),
which were characterized by analytical and various spectro-
scopic techniques. X-ray diﬀraction structures of HL1, HL2,
HL4−HL6, and 1, 3−6 were established, and solution
equilibria studies for HL1 and Cu(II) complex formation
with HL1 by pH-potentiometry, UV−vis, electron para-
magnetic resonance (EPR), and 1H NMR spectroscopy, as
well as electrochemistry, were performed. Antiproliferative
activity against human ovarian cancer A2780 and cisplatin
resistant A2780cis cell lines, noncancerous HEK293 cell line,
as well as antibacterial activity against Gram-positive
(Staphylococcus aureus) compared with Gram-negative bacteria
(Pseudomonas aeruginosa) were investigated and structure−
Chart 1. Line Drawings of Proligands HL1−6 and Cu(II) Complexes [Cu(L1−6)Cl] (1−6) Reported in This Worka
aAll proligands and Cu(II) complexes, but HL3 and 2, were investigated by single-crystal X-ray crystallography.
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activity relationships were discussed. The processes controlling
cellular accumulation of 2 were investigated. Preliminary
insights into the mode of action of 2 and 5, including mouse
R2 RNR inhibitory potential, studied by molecular modeling
and tyrosyl radical quenching monitored by EPR spectroscopy,
as well as by western blotting and ﬂow cytometry, are also
presented.
2. RESULTS
2.1. Synthesis and Characterization of (Iso)TSC−
Morpholine Hybrids and Their Cu(II) Complexes. The
5-methylmorpholine-pyridine-2-carboxaldehyde H was pre-
pared in seven steps as shown in Scheme 1, and the detailed
synthesis is described in the Supporting Information. First,
pyridine-2,5-dicarboxylic acid A was converted into diester B
that was further reduced to the diol C. The latter was
selectively oxidized with SeO2 to the aldehyde D. After
protection of the aldehyde group, the alcohol E was converted
into the chloride F that was further reacted with morpholine to
give species G. Finally, the hydrolysis of the methyl ester
function in acidic conditions aﬀorded the required aldehyde H
for condensation reactions with thiosemicarbazide, 4N-
dimethyl-3-thiosemicarbazide, 4N-pyrrolydinyl-3-thiosemicar-
bazide, 4N-morpholinyl-3-thiosemicarbazide, 4N-phenyl-3-thi-
osemicarbazide, and S-methylisothiosemicarbazide hydroio-
dide to give the hybrids HL1−6 (Chart 1), respectively. One-
and two-dimensional NMR spectra were in agreement with the
proposed structures for HL1−6, enabling the assignment of all
1H and 13C resonances. The ESI mass spectra recorded in a
positive ion mode showed strong peaks corresponding to [M +
H]+ and [M + Na]+ ions, respectively. The proligands HL1−6
were reacted with Cu(II) chloride dihydrate and triethylamine
in 1:1:1 mole ratio in methanol to give [Cu(L1−6)Cl] (1−6) in
35−91% yields (Chart 1). Positive ion ESI mass spectra
showed strong peaks attributed to [Cu(L1−6)]+ ions. The
structures of 1, 3−6 were also established by single-crystal X-
ray diﬀraction (vide infra).
2.2. X-ray Crystallography. The results of X-ray
diﬀraction studies of HL1, HL2, and HL4−6 are shown in
Figure S1, whereas those of [Cu(L1)Cl] (1), [Cu(L3)Cl] (3),
[Cu(L4)Cl] (4), [Cu(L5)Cl] (5), and [Cu(L1)Cl(H2O)]
(1′), [Cu(L6)Cl] (6) are shown in Figures 1 and 2,
respectively. Selected bond distances and bond angles are
quoted in Tables S1 and S2. The proligands adopted diﬀerent
isomeric conﬁgurations in the solid state depending on
substituents at the terminal nitrogen atom of the thiosemi-
carbazide moiety. Complexes 1, 3, 4, and 5 form dimeric
associates as shown in Figure 1 (co-crystallized solvent was
omitted for clarity). Each Cu(II) ion has a distorted square-
planar coordination geometry. Intermolecular contacts sup-
porting the dimeric associates in the crystals are of diﬀerent
nature in 1 and 3−5, respectively. The presence of long
intermolecular contacts Cu···Cl or Cu···Cl and Cu···S (see
legend to Figure 1) provides evidence of weak association of
complexes in dimers, which most probably dissociate in
solution with formation of monomeric species. There was no
evidence from ESI mass spectra on the presence of dimeric
species in solution.
Moreover, HL1 reacts with CuCl2 in aqueous solution with
formation of ﬁve-coordinate complex [Cu(L1)Cl(H2O)] (1′·
2H2O) (Figure 2a). The monomeric square-planar complex
[Cu(L6)Cl] forms an inﬁnite chain via weak coordination of
the morpholine oxygen atom of one complex to the Cu(II)
atom of the next molecule as shown in Figure S2. The
intermolecular Cu···O contact is of 2.603(3) Å.
2.3. Solution Chemistry. To establish the presence of
isomers of the proligands in aqueous solution and proton
dissociation processes, in which these can be involved, solution
equilibrium studies have been performed. Likewise, the
solution speciation of the copper(II) complexes, as well as
their stability have been investigated to elucidate the species,
which is the most stable and abundant at physiological pH.
The proligand HL1 (Chart 1) was chosen for the detailed
solution equilibrium studies because it has the simplest
structure and the best aqueous solubility among the proligands
prepared. The presence of diﬀerent isomers in solution was
excluded by measurements of 1H NMR spectra in 10% D2O/
90% H2O (Figure S3), which showed only one set of signals
for the proligand in accordance to its low (C1) molecular
symmetry. The proligand most probably adopts the E
conﬁguration found in the solid state (Figure S1). The same
conﬁguration was reported previously for the reference
compound 2-formylpyridine thiosemicarbazone in polar
solvents.25 Proton dissociation processes were monitored in
aqueous solution by pH-potentiometric and 1H NMR
titrations and three pKa values were determined by both
methods (Table S3). According to the obtained pKa values,
HL1 is mainly neutral (97% HL, 3% H2L
+) at physiological pH
(Figure S4). Inspection of 1H NMR spectra revealed stepwise
deprotonation of three functional groups in the following
order: NpyridiniumH
+ → NmorpholiniumH
+ → NhydrazineH (Figure
S3).
Scheme 1. Synthesis of 5-Methylmorpholine-pyridine-2-carboxaldehydea
aReagents and conditions: (i) thionyl chloride, methanol, 0 °C→ room temperature, 12 h;22 (ii) sodium borohydride, ethanol, acetone, potassium
carbonate, chloroform, 0 °C, 1 h → reﬂux, overnight;23 (iii) selenium dioxide, dioxane, water, 100 °C, 3 h;24 (iv) trimethyl orthoformate,
methanesulfonic acid, methanol, reﬂux, 48 h; (v) thionyl chloride, dichloromethane, −80 °C → room temperature, overnight; (vi) moprholine,
triethylamine, tetrahydrofuran/CH2Cl2 1:1, 50 °C, overnight, puriﬁcation by column chromatography; and (vii) HCl, water, 60 °C, overnight.
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The solution speciation of the Cu(II) complexes with HL1
was characterized by the combined use of pH-potentiometry,
UV−vis spectrophotometry [via charge transfer (CT) and d−d
bands], and EPR spectroscopy. The spectral changes (Table
S4, Figures 3a and S5) in the UV and visible regions measured
at 1:1 metal-to-ligand ratio show the high-extent formation of a
Cu(II) complex already at strongly acidic pH values (e.g., pH
1) and its stepwise deprotonation by increasing the pH. At pH
7.4, the dominant species is [CuL]+ (Figure 3b).
Because of the high stability of the Cu(II) complexes
formed, the cumulative constant (log β) for the [CuL]+ species
(Table S4) was determined via ethylenediaminetetraacetic acid
(EDTA) displacement studies (Figure S6). Then, the pKa and
the log β values for the other type of complexes ([CuLH2]
3+,
[CuLH]2+, [CuLH−1]) were computed using each method,
and data were in a fairly good agreement (Table S4). It is
worth noting that formation of a bis-ligand complex [CuL2] at
ligand excess was also conﬁrmed by the UV−vis CT and EPR
titrations. The d−d bands (Figure S5) recorded from pH 3.4
to 7.5 at 1:1 metal-to-ligand ratio revealed that the proton
dissociation process of [CuLH]2+ → [CuL]+ is accompanied
by rather weak spectral changes as most probably the
noncoordinating morpholinium NH+ is deprotonating. To
further characterize, the coordination modes of the various
complexes in solution EPR parameters (Table S5) obtained by
the deconvolution of the recorded spectra (Figure S7) were
analyzed. The isotropic g and A values of [CuLH]2+ and
[CuL]+ are quite similar, indicating the like coordination
mode.
Comparison of the EPR parameters of the Cu(II) complexes
of HL1 with those of 2-formylpyridine thiosemicarbazone25
and triapine26 permitted to conclude that in the [CuLH]2+ and
[CuL]+ complexes a typical coordination mode via the Npyridyl,
N, S− binding site is realized in accordance with the X-ray
diﬀraction data. [CuLH2]
3+ contains the diprotonated ligand in
which the protons are attributed to the noncoordinating N2H
and morpholinium NH+ moieties, while [CuLH‑1] is most
probably a mixed hydroxido complex [CuL(OH)] formed by
the deprotonation of water molecule coordinated in the fourth
equatorial position. At ligand excess besides the bis-ligand
complex, a minor dinuclear species [Cu2L3H]
2+ was detected
resulting in the weak exchange coupling between neighboring
Cu(II) centers smearing out the expected hyperﬁne structure.
2.4. Cu(II)−TSC Complexes Undergo Quasi-Reversible
One-Electron Reduction at Biologically Accessible
Potentials. To assess the redox properties of 1−6, detailed
electrochemical and spectroscopic studies in various solvents
were performed using cyclic voltammetry as well as EPR-
spectroelectrochemistry. Additionally, the UV−vis spectra of
1−5 were measured (Figure S8). Electrochemical and
spectroscopic data are summarized in Table S6. Almost
reversible one-electron cathodic reduction was observed for
1−5 in dimethyl sulfoxide (DMSO) with half-wave redox
potentials from −0.77 to −0.81 V versus Fc+/Fc [for
Figure 1. ORTEP views of weak dimeric associates of (a) [Cu(L1)Cl]
(1), (b) [Cu(L3)Cl] (3), (c) [Cu(L4)Cl]2 (4), and (d) [Cu(L
5)Cl]
(5).
Figure 2. ORTEP views of (a) [Cu(L1)Cl(H2O)] (1′) and (b)
[Cu(L6)Cl] (6).
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comparison from −0.13 to −0.17 V vs normal hydrogen
electrode (NHE)] (Table S6 and Figure S9). In general, the
values of redox potentials of 1−6 for the ﬁrst reduction step
decreased in the following rank order (E1/2(5) > E1/2(2) =
E1/2(3) = E1/2(4) > E1/2(1) > E1/2(6)). The second reduction
step occurred at −1.8 V versus Fc+/Fc (−1.16 V vs NHE) and
was less reversible, indicating a ligand-based reduction. This
was conﬁrmed by the CVs of the corresponding proligands
which exhibited the ﬁrst reduction step at around −1.9 V
versus Fc+/Fc (not shown). In aqueous solutions, the
reduction potentials shifted to the less negative values, and
reduction was less reversible as shown for 2 in Figure S10.
Complex 6 exhibited diﬀerent redox behavior with the lowest
electrochemical reversibility and the most negative reduction
potential of −0.86 V versus Fc+/Fc (−0.26 V vs NHE) (Figure
S9c). Unlike the cathodic reduction, the anodic oxidation of
1−6 was irreversible with potential values in the region from
0.4 to 0.8 V versus Fc+/Fc (0.68 V to 1.44 V vs NHE). A
similar response was observed for the corresponding proligand
HL2 (Figure S11), indicating ligand based oxidation in 2.
2.5. Biologically Accessible Reduction of Cu(II)−TSC
Complexes is Cu-Centered. To investigate whether the
biologically accessible reduction is metal-centered, the
reversible one-electron reduction of 5 was further studied by
in situ UV−vis-spectroelectrochemistry (Figure 4a). Upon
cathodic reduction at the ﬁrst reduction peak, two isosbestic
points at 389 and 325 nm were detected. The spectral changes
of the S→ Cu(II) CT bands (∼425 nm) clearly conﬁrmed the
reduction of Cu(II) to Cu(I). Additionally, upon voltammetric
reverse scan, reoxidation and a nearly full recovery of the initial
optical bands were observed, attesting the chemical reversi-
bility of the cathodic reduction even at low scan rates (Figure
4). To conﬁrm the involvement of Cu(II) in the reduction
processes, in situ EPR electrochemistry of 1−6 in nBu4NPF6/
DMSO and water was performed because metal-based
reduction would result in the formation of EPR-silent Cu(I)
species (Figure 4b). As can be seen for electrochemical
reduction of 2 in nBu4NPF6/DMSO in the region of the ﬁrst
one-electron reduction step (see inset in Figure 4b), a
signiﬁcant decrease of EPR signal was observed in accord
with the formation of a diamagnetic Cu(I) d10 complex. For
aqueous solutions, the reversibility was signiﬁcantly reduced,
implying a more complex mechanism involving the release of
the proligand. However, by decreasing the scan rate and going
to the more positive potentials upon reverse scan, a partial
recovery of the initial optical bands was also observed in
aqueous solutions as shown for 2 in Figure S12. Thus,
electrochemical data indicated a likely reduction of Cu(II)−
TSC complexes to Cu(I) species with the subsequent release
of the proligands.
2.6. Lead TSCs and Their Cu(II) Complexes Exhibited
Marked Antiproliferative Activity in a Nanomolar
Concentration Range. The in vitro anticancer activity of
1−6 and their respective TSCs was determined in ovarian
carcinoma cells (A2780 and A2780cisR) and noncancerous
human embryonic kidney cells (HEK293) by the colorimetric
MTT assay with an exposure time of 72 h. The IC50 values for
HL1−HL6 and 1−6 in comparison with triapine, CuCl2, Cu-
triapine and cisplatin are listed in Tables 1 and 2, respectively,
and concentration−eﬀect curves are depicted in Figure S13.
With the exception of HL1 and HL6, the proligands
demonstrated marked antiproliferative activity in a submicro-
Figure 3. UV−vis spectra recorded for the Cu(II)−HL1 (1:1) system at various pH values (a), and concentration distribution curves and measured
absorbance values at 346 nm (⧫) and 440 nm (■) for the same system (b). {cCu(II) = clig = 121 μM; T = 298 K; I = 0.10 M (KCl); l = 0.5 cm}.
Figure 4. Spectroelectrochemistry of 2 in nBu4NPF6/DMSO in the
region of the ﬁrst cathodic peak. (a) Potential dependence of UV−vis
spectra with respective cyclic voltammogram (Pt-microstructured
honeycomb working electrode, scan rate v = 5 mV s−1); (b) evolution
of UV−vis spectra in 2D projection in forward scan (inset: EPR
spectra measured at the ﬁrst reduction peak using Pt mesh working
electrode).
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molar to nanomolar concentration range in both A2780 and
A2780cisR cells. The eﬃcacy of compounds HL2, HL3, and
HL5 in cisplatin-resistant A2780cisR cells decreased by factor
3.5 in comparison to that in sensitive A2780 cells, whereas a
4.6- and 11-fold drop of activity was observed for triapine and
HL4, respectively. The activity of proligands HL1−6 and
triapine increased in the following rank order HL6 < HL1 <
triapine < HL5 < HL4 ≪ HL2 ≈ HL3 (Table 1).
As can be seen in Table 2, with the exception of 3, all
Cu(II)−TSC complexes were equally or more cytotoxic than
the respective proligands. The activity of complexes 1−6
increased in the following order 6 < 1 < 3 < 4≪ 2 < 5, similar
to the trend in electrochemical redox potentials for Cu-based
reduction step (Table S6). To compare the cytotoxicity of 1−6
with that of [Cu(H2O)6]
2+, A2780 cells were treated with
aqueous solution of CuCl2. In agreement with the literature,
29
CuCl2 revealed antiproliferative activity in the high micromolar
range, in contrast to high activity of 1−6, which should be
regarded as individual entities with their own biological,
pharmacokinetic, and metabolic proﬁles. Complexes 1−6 were
up to ∼50 times more cytotoxic than cisplatin in A2780 cells
and up to ∼270 times more cytotoxic in A2780cisR cells.
Additionally, the diﬀerences in cytotoxicity of 1−6 in A2780
and A2780cisR cells were signiﬁcantly lower than that for
HL1−HL6 and cisplatin, indicating high potential of Cu(II)
complexes for the treatment of cisplatin-resistant tumors. The
most active TSC proligands and their respective Cu(II)
complexes were more selective toward A2780 cells over
HEK293 cells; however, they did not show any selectivity
toward A2780cisR cells over HEK293 cells. On the contrary,
triapine was signiﬁcantly more cytotoxic toward noncancerous
HEK cells than A2780 or A2780cis cells.
2.7. Antiproliferative Activity of Cu(II)−TSC Com-
plexes Correlates with Their Cellular Accumulation and
Lipophilicity. The ability of anticancer drugs to penetrate
biological membranes, tissues, and barriers underlies their
biological, pharmacokinetic, and metabolic properties. These
properties can be predicted by calculating physicochemical
characteristics of drug candidates using molecular descrip-
tors.30 To estimate if the proligands HL1−HL6 and
corresponding Cu(II) complexes demonstrate drug-like
properties, they were evaluated with main stream molecular
descriptors, such as molecular weight, number of hydrogen
bond donors and acceptors (HBA), n-octanol−water partition
coeﬃcient (log P), polar surface area, and rotatable bonds. The
results are shown in Table S7 in the Supporting Information.
On the basis of the calculated physicochemical parameters, we
determined if novel compounds belonged to the drug-like
Table 1. Cytotoxicity of Proligands HL1−6 and Their n-Octanol/Water Distribution Coeﬃcients (log D7.4)
IC50 [μM]
a
compound A2780 A2780cis RFb HEK293 SFc log D7.4
d
HL1 7.6 ± 1.9 13 ± 1 1.7 9.1 ± 1.7 1.2 +0.46 ± 0.01
HL2 0.010 ± 0.001 0.035 ± 0.006 3.5 0.030 ± 0.005 3.0 +0.51 ± 0.02
HL3 0.008 ± 0.002 0.028 ± 0.006 3.5 0.022 ± 0.005 2.8 +1.0 ± 0.1
HL4 0.07 ± 0.01 0.76 ± 0.06 10.9 0.35 ± 0.05 5.0 +0.37 ± 0.04
HL5 0.31 ± 0.08 1.1 ± 0.2 3.5 0.67 ± 0.06 2.2 ≥2
HL6 157 ± 21 426 ± 44 2.7 89 ± 2 0.6 +0.84 ± 0.01
triapine 0.67 ± 0.22 1.1 ± 0.1 4.6 0.39 ± 0.05 0.6 n.d.e
a50% inhibitory concentrations (IC50) in human ovarian carcinoma cell lines A2780 and A2780cisR and human embryonic kidney cell line
HEK293, determined by the MTT assay after 72 h exposure. Values are means ± standard deviations (SDs) obtained from at least three
independent experiments. bResistance factor (RF) is determined as IC50(A2780cisR)/IC50(A2780).
cSelectivity factor (SF) is determined as IC50(HEK293)/
IC50(A2780).
dDistribution coeﬃcients for n-octanol and buﬀered aqueous solution determined at physiological pH by UV−vis spectroscopy. Values
are means ± SDs obtained from at least three independent experiments. en.d.not determined.
Table 2. Cytotoxicity of Cu(II)−TSC Complexes 1−6, CuCl2 and Cisplatin and Their n-Octanol/Water Distribution
Coeﬃcients (log D7.4)
IC50 [μM]
a cellular accumulation,d nmol Cu/mg protein
compound A2780 A2780cis HEK293 RFb SFc A2780 log D7.4
e
1 2.2 ± 0.1 13 ± 4 16 ± 2 5.9 7.3 0.63 ± 0.09 −0.81 ± 0.04
2 0.012 ± 0.002 0.030 ± 0.003 0.032 ± 0.008 2.5 2.7 3.9 ± 0.6 +0.30 ± 0.01
3 0.26 ± 0.02 0.60 ± 0.05 0.78 ± 0.20 2.3 3.0 2.2 ± 0.6 +0.86 ± 0.02
4 0.08 ± 0.01 0.26 ± 0.04 0.24 ± 0.02 3.3 3.0 3.2 ± 0.7 +0.12 ± 0.01
5 0.009 ± 0.002 0.017 ± 0.002 0.020 ± 0.003 1.9 2.2 4.1 ± 0.9 +1.49 ± 0.06
6 43 ± 3 62 ± 6 72 ± 0 1.4 1.7 0.47 ± 0.08 −0.23 ± 0.01
CuCl2 83 ± 12 82 ± 3 187 ± 37 1.0 2.3 0.17 ± 0.05
f n.d.g
Cu-triapineh 1.3 ± 0.1 29 ± 0.3 n.d. 22.3 − n.d. n.d.
cisplatin 0.44 ± 0.13 4.6 ± 0.3 n.d. 10.5 − − −2.30 ± 0.79i
a50% inhibitory concentrations (IC50) in human ovarian carcinoma cell lines A2780 and A2780cisR and human embryonic kidney cell line
HEK293, determined by the MTT assay after exposure for 72 h. Values are means ± SDs obtained from at least three independent experiments.
bRF is determined as IC50(A2780cisR)/IC50(A2780).
cSF is determined as IC50(HEK293)/IC50(A2780).
dCellular accumulation in A2780 cells, determined by
Inductively Coupled Plasma Mass Spectrometry (ICP−MS) after 24 h exposure at concentration of 1 μM. Values are means ± SDs obtained from
at least three independent experiments. eDistribution coeﬃcients for n-octanol and buﬀered aqueous solution determined at physiological pH by
UV−vis spectroscopy. Values are means ± SDs obtained from at least three independent experiments. fCellular accumulation of CuCl2 was
detected at concentration of 2.5 μM. gn.d.not determined. hThe IC50 values (exposure for 72 h) were taken from the ref 27. ilog Po/w value was
taken from the ref 28.
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chemical space, which is commonly deﬁned by the well-known
Lipinski rule, or to the known drug space (KDS), which
includes all small compounds in medical use.31 As can be seen
from Table S7, all compounds fell within the boundaries of
drug-like chemical space with the exception of HL4 which
demonstrated higher HBA value, referring to KDS space. On
the basis of these results, novel compounds are expected to be
suﬃciently cell permeable. Following the calculations, we
determined the lipophilicity of all compounds experimentally
(log D7.4, Tables 1 and 2). It is known that cancer cells
accumulate hydrophilic compounds to a smaller extent relative
to hydrophobic compounds, thereby aﬀecting their activity.
Hence, the diﬀerences in the lipophilicity of compounds might
be related to the observed trends in cytotoxicity of 1−6. In
general, with the exception of morpholine derivative HL4,
proligands which were obtained by systematic substitution at
the terminal thioamide nitrogen demonstrated higher lip-
ophilicity when compared with that of HL1. As expected,
proligands were more lipophilic than the corresponding Cu(II)
species, which are positively charged at physiological pH
(Figure 3b). Among Cu(II)−TSC complexes, only the least
cytotoxic complexes 1 and 6, as well as cisplatin, demonstrated
negative log D7.4 values, indicating their higher hydrophilicity.
The lipophilicity of 2−5 increased in the following order 4 < 2
< 3 < 5, and correlated well with their cytotoxicity in cancer
cells, with the exception of 3. Subsequently, we determined the
total cellular accumulation of Cu in A2780 cells by ICP−MS
upon 24 h exposure to 1−6 in comparison with CuCl2 (Table
2). The IC50 values from MTT assays with 72 h drug exposure
varied from nanomolar to high micromolar concentrations;
therefore, in the cellular accumulation experiment cells were
treated with 1 μM of compounds of interest for 24 h to
minimize cell detachment. The cellular accumulation of all
Cu(II)−TSC complexes was signiﬁcantly higher than for
CuCl2, indicating the role of lipophilic TSC ligands in the
delivery of the complexes into the cells. The accumulation
increased in the order 6 < 1 < 3 < 4 < 2 < 5.
2.8. Cellular Accumulation and Eﬄux of Cu(II)−TSC
Complexes are Energy- and/or Temperature-Depend-
ent Processes. Dependence of cytotoxicity on lipophilicity of
1−6 indicates that their cellular accumulation at least partially
occurs via passive diﬀusion. In order to gain additional insights
into the mechanisms controlling the accumulation of Cu(II)−
TSC complexes, we investigated the eﬀects of temperature and
various inhibitors on total cellular accumulation of 2 with the
results shown in Figure 5. A2780 cells were treated with 2 at 3
μM for 30, 60 and 120 min at 37 and 4 °C and intracellular Cu
content was measured by ICP−MS. Prolonged incubation at
low temperatures may result in the changes in membrane
ﬂuidity, decreasing membrane permeability and restricting
drug uptake;32 therefore, the shorter time point of 10 min was
also included. The cellular accumulation of 2 dramatically
decreased at low temperature even after 10 min treatment,
indicating the involvement of active carrier-mediated transport
or facilitated diﬀusion. Likewise, the decrease of cellular
accumulation at low temperatures has been reported for both
Cu(II)−TSC complexes and metal-free TSCs.33,34 To further
clarify whether the uptake of 2 requires energy, the cellular
ATP production was blocked by incubating cells in a saline
solution [Hank’s Balanced Salt Solution (HBSS)], resulting in
total starvation and rapid reduction of intracellular ATP
content, and/or by addition of oligomycin, leading to the
inhibition of oxidative phosphorylation.
When A2780 cells were pretreated with 5 μM of oligomycin
for 1 or 4 h and subsequently co-treated with 3 μM of 2, the
intracellular Cu levels were not aﬀected, even though the
mitochondrial respiration of the cancer cells was successfully
inhibited (data not shown). However, when A2780 cells were
starved in HBSS for 1 h and subsequently treated with 3 μM of
2 for 1 h, an increase in intracellular Cu content was observed.
Co-treatment of 2 with 5 μM of oligomycin in HBSS did not
result in a further increase of intracellular Cu levels. The
increase of the Cu content in HBSS-starved cells might stem
from the inhibition of energy-dependent eﬄux processes. To
assess the role of proteins in both cellular accumulation and
eﬄux of 2, A2780 cells were pretreated with cycloheximide,
which is a known inhibitor of protein synthesis. Signiﬁcant
increase of intracellular Cu content was observed, similar to
HBSS starvation, providing further evidence for the involve-
ment of protein-dependent eﬄux processes. Similar eﬀects
have been reported for related Cu(II)−TSC complexes.33 The
data provide evidence that cellular accumulation of 2 occurs
via carrier-facilitated diﬀusion, which might co-exist with
passive permeation through the lipid bilayer.35 The eﬄux
processes, however, are actively mediated by proteins and upon
inhibition of protein synthesis or energy production a strong
increase of intracellular Cu concentration was observed.
Figure 5. Eﬀects of temperature and inhibitors on the accumulation of 2 in A2780 cells. Intracellular content was determined by ICP−MS: (a)
A2780 cells were treated with 2 (3 μM) at 37 or 4 °C for the indicated time periods. (b) A2780 cells were pre-treated with oligomycin (5 μM),
and/or pre-incubated in HBSS for 1 h, or pretreated with cycloheximide (100 μM) for 4 h and subsequently co-treated with 2 (3 μM) for 1 h. The
presence of inhibitors did not show any eﬀects on the intracellular Cu level of untreated A2780 cells (data not shown). Statistical analysis was
performed by two-tailed T-test using GraphPad Prism software (GraphPad Software Inc., CA) with p < 0.05 considered as signiﬁcant (*p < 0.05,
**p < 0.01).
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2.9. Cu(II)−TSC Complexes Demonstrated High
Antibacterial Activity Against S. aureus in a Compara-
ble Concentration Range to Ciproﬂoxacin. The anti-
bacterial activity of HL1−HL6 and 1−6 on planktonic cells of
P. aeruginosa and S. aureus was investigated by determination
of minimal inhibitory concentration (MIC)50 and MIC100
values (Table 3). Overall, compounds showed a higher
antimicrobial activity against Gram-positive (S. aureus)
compared with Gram-negative bacteria (P. aeruginosa). The
highest activity against S. aureus was observed for 2−5, which
speciﬁcally inhibited its growth with MIC50 values ranging
between 2 and 5 μg/mL and completely abolished its growth
at 10 μg/mL (MIC100). This activity is comparable but slightly
lower than the antibacterial activity of a well-known
benchmarked antibiotic ciproﬂoxacin (CPX). On the contrary,
P. aeruginosa exhibited high resistance to most of the
compounds tested with the exception of HL2 and 2 with
MIC50 values at 70 and 50 μg/mL, respectively.
Compounds HL6 and 6 based on S-methylisothiosemicar-
bazide were completely devoid of antibacterial activity and no
inhibition of bacterial growth was observed at the whole
concentration range tested. Interestingly, metal-free TSCs
HL1−HL5 displayed relatively low antibacterial activity
(MIC100 > 300 μg/mL), which was signiﬁcantly enhanced
upon coordination to Cu(II). Subsequently, the mode of
action of the most active compounds 2−5 was evaluated in S.
aureus and P. aeruginosa using the Live/Dead viability assay. As
shown in Figure 6, compounds 2−5 greatly reduced cell
replication, reﬂected by the lower number of cells compared
with the untreated sample and high percentage of propidium
iodide (PI)-stained cells, indicating compromised cell mem-
brane allowing the penetration of PI and a bacteriostatic action
of these compounds.
2.10. TSCs and Their Cu(II) Complexes Are Located in
a Close Proximity to the Active Site of Mouse R2 RNR
Protein. Next, the RNR inhibitory potential of the TSC
proligands HL1−HL6 and their corresponding Cu(II)
complexes 1−6 was investigated. The proligands HL1−HL6
and Cu(II) complexes 1−6 were docked into the crystal
structure of mouse R2 RNR subunit (PDB ID: 1W68)36 using
GOLD software.37 To predict the binding of 1−6, the
GoldScore function was used and its parameters were modiﬁed
to include Cu because they are not in GOLD’s database.38 The
results of the scoring functions are presented in Table S8.
Overall, similar docking results were observed for all proligands
and their Cu(II) complexes, suggesting a plausible binding to
the mouse R2 protein. The compounds were deeply embedded
into the pocket of the R2 subunit, close to the diferric center
(Fe2O), and the enzymatically essential tyrosyl residue
(Tyr177). The docked conﬁguration of 5 in comparison with
triapine into the binding site is shown in Figure 7. An overlap
with triapine was predicted, resulting in a partial reproduction
of a hydrogen-bonding pattern (Figure S14, Table S8).
2.11. Lead TSCs and Their Cu(II) Complexes Cause
Moderate Inhibition of a Mouse R2 RNR Protein in a
Reducing Environment as a Result of Iron Chelation.
Table 3. Antibacterial Activity of HL1−6 and 1−6a
S. aureus (μg/mL) P. aeruginosa (μg/mL)
MIC50 MIC100 MIC50 MIC100
HL1 100 >400 NA NA
HL2 10 400 50 100
HL3 10 300 100 NA
HL4 100 >400 NA NA
HL5 10 300 NA NA
HL6 NA NA NA NA
1 100 >500 NA NA
2 2 10 70 200
3 3 10 100 400
4 5 10 100 400
5 3 10 200 450
6 NA NA 200 NA
CPX 0.5 1 0.5 2
aSee Experimental Section for details. NA denotes no antibacterial
activity detected (>500 μg/mL).
Figure 6. Live/dead bacterial cells are shown by staining with green ﬂuorescence indicating live cells and red ﬂuorescence indicating dead cells.
Figure 7. Overlay of docked conﬁgurations of Cu(II) complex 5
(gray) and triapine (green) in the binding site of the mouse R2 RNR
protein (PDB ID: 1W68). The surface is rendered. Blue and brown
depict hydrophilic and hydrophobic areas, respectively.
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The eﬀects of the most cytotoxic complexes 2 and 5, and the
corresponding proligands HL2 and HL5, on the mouse R2
tyrosyl radical were investigated by EPR spectroscopy at 30 K.
The proligands and their Cu(II) complexes were incubated
with the mouse R2 RNR protein at 1:1 protein-to-compound
mole ratio at 298 K in the presence or absence of the reducing
agent dithiothreitol (DTT), and the time-dependent reduction
of the tyrosyl radical was monitored.39 Tyrosyl radical
reduction by the investigated compounds was observed only
in the presence of DTT. Upon incubation with HL2, HL5, and
2, 5, 50% of tyrosyl radical was reduced within 90 s, after which
no further reduction was observed (Figure S15). Because the
diferric center of the mouse R2 protein is expected to be
reduced upon addition of DTT,40,41 the ability of proligands
HL2 and HL5 to form stable Fe(II) complexes was investigated
by monitoring these reactions by UV−vis measurements in
buﬀered aqueous solutions at pH 7.4. HL2 and HL5 (λmax =
312 and 320 nm, respectively) readily reacted with FeSO4·
7H2O aﬀording Fe(II) bis-ligand complexes (λmax = 373, 610
nm and λmax = 385, 645 nm, respectively) at both 1:1 and 1:2
Fe-to-ligand mole ratios. Additionally, the formation of Fe(III)
complexes with the subsequent reduction by DTT was
investigated (Figure S15). HL2 and HL5 reacted with FeCl3·
6H2O (at 1:1 or 1:2 Fe-to-ligand mole ratios) to give
[FeIII(L2)2]
+ and [FeIII(L5)2]
+ complexes (λmax = 378 nm,
612 nm and λmax = 386 nm, 635 nm, respectively). The
formation of [FeIII(L5)2]
+ species was conﬁrmed by ESI-MS
(Figure S16). The absorption spectra of reduced forms were
almost identical to those of Fe(II) bis-ligand species and to the
previously reported spectra of other FeII−TSC complexes.42
2.12. HL2 and 2 Induced Unfolded Protein Response,
Antioxidant Defense, and Cell Cycle Perturbations. To
get further insights into the mechanism of action of 2, Western
blotting of endoplasmic reticulum (ER) stress-related protein
markers, namely, IRE1α, CHOP, BiP/GRP78, and p-ERK 1/2,
were performed (Figure 8). When A2780 cells were treated
with increasing concentrations of 2 for 24 h, the dose-
dependent upregulation of IRE1α and CHOP proteins,
decrease of ER stress chaperone BiP/GRP78, and phosphor-
ylation of ERK were observed as a response to ER stress. To
assess the eﬀects of 2 on the cell cycle, we examined the
expression of cyclin D1 and cyclin B1 which serve as cell cycle
regulatory switches in actively proliferating cells and are
required for cell cycle progression in G1 and G2 phases,
respectively. Complex 2 displayed signiﬁcant inhibition of
cyclin D1 expression, indicating cell cycle arrest at G1/S phase,
whereas no changes in cyclin B1 expression were detected.
Subsequently, we compared the eﬀects of 2 and the respective
proligand HL2 on the expression of p-ERK1/2 and the marker
of antioxidant defence NRF2. Both HL2 and 2 demonstrated
phosphorylation of ERK1/2; however, the eﬀects on NRF2
were markedly diﬀerent. Whereas no increase of NRF2
expression was observed, when cells were treated with HL2,
complex 2 induced increased expression of NRF2 even at low
concentration, indicating activated antioxidant defense,
possibly as a result of reactive oxygen species (ROS) insult
caused by Cu(II) reduction.
2.13. HL2 and 2 Induced Dose-Dependent Apoptosis
Accompanied by Poly(ADP-ribose)polymerase-1 Cleav-
age and XIAP Inhibition. To elucidate if observed
Figure 8. Western blot analysis of various proteins. A2780 cells were treated with increasing concentrations of proligand HL2 and complex 2
(corresponding to IC50 value from MTT experiment with exposure time of 72 h) for 24 h. Total lysates were isolated and examined by Western
blot. Actin was used as a loading control.
Figure 9. Bar graphs showing the percentage of cell death due to apoptosis (left) and necrosis (right) in A2780 cells treated with increasing
concentrations of HL2, 2 (2IC50 and 6IC50) and CuCl2 and detected by Annexin V/PI apoptosis assay. Statistical analysis was performed by two-
tailed T-test using GraphPad Prism software (GraphPad Software Inc., CA) with p < 0.05 considered as signiﬁcant (*p < 0.05, **p < 0.01).
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cytotoxicity of new compounds described in this study was a
result of apoptosis induction, we conducted Annexin V/PI
apoptosis assay. In brief, ﬂuorochrome-labeled Annexin V
reagent is used for detection of membrane phosphatidylserine
(PS), which translocates to the cellular surface from the inner
side of plasma membrane in the event of early apoptosis.
Simultaneously, PI is used for detection of later stages of
apoptosis or necrosis, which are characterized by loss of
membrane integrity and accumulation of PI inside the cells.
A2780 cells were treated with 2IC50 and 6IC50 concentrations
of HL2 and 2 (IC50 values were obtained from MTT
experiment in A2780 cells with the exposure time of 72 h).
Results are illustrated in Figure 9. Upon incubation of A2780
cells with increasing concentrations of HL2 and 2, the dose-
dependent increase of apoptotic cells was observed.
At low concentrations, both the proligand and Cu(II)
complex induced a two- to three-fold increase of apoptotic
cells in comparison with untreated cells [7.8 ± 1.8, 17.2 ± 3.9,
and 22.5 ± 5.3% for untreated cells, HL2 (2IC50) and 2
(2IC50), respectively]. At high concentrations, a further
increase of apoptotic cells was observed [28.1 ± 4.0 and
24.4 ± 7.8.% for HL2 (6IC50) and 2 (6IC50)]. No signiﬁcant
diﬀerences between the apoptosis-inducing properties of the
proligand HL2 and 2 were noticed. When CuCl2 was incubated
with the cells at the concentration, corresponding to Cu
content in 2 at 2IC50, no induction of apoptosis was detected,
which can be explained by poor cellular accumulation of
CuCl2. The proportion of necrotic cells was negligible and no
signiﬁcant deviation from untreated cells was detected;
therefore, the induction of necrosis by HL2 and 2 was ruled
out. Subsequently, the eﬀects of HL2 and 2 on apoptotic
signaling in cells were investigated by western blotting. A2780
cells were treated with increasing concentrations of the drug
for 24 h, and the cleavage of poly(ADP-ribose)polymerase-1
(PARP) was investigated (Figure 8). Cleavage of PARP
through suicidal proteases such as caspases has been widely
accepted as an indicator of apoptosis.43 As can be seen in
Figure 8, both HL2 and 2 revealed a dose-dependent PARP
cleavage, indicating apoptosis induction in agreement with the
results of Annexin V/PI assay. Additionally, expression of X-
linked inhibitor of apoptosis (XIAP) was markedly reduced in
a dose-dependent manner upon treatment with increasing
concentrations of 2.
3. DISCUSSION
The diverse biological and chemical properties of triapine and
other TSCs, as well as their transition-metal complexes, have
been extensively studied for decades.41,44−51 Their antiprolifer-
ative and antibacterial activity varies greatly, from low
nanomolar to high micromolar range, depending on the
substituents at the TSC backbone.16,20,52 Even though clinical
trials demonstrated some beneﬁts of patient treatment with
triapine, its low aqueous solubility and high toxicity prevent it
from further clinical progress. In a continuous eﬀort to
improve the bioavailability and therapeutic proﬁle of TSCs and
Cu(II)−TSC complexes, novel TSC hybrids with bioactive L-
proline, homoproline, piperazine, or iminodiacetate moieties,
using the molecular hybridization approach, have been
designed and synthesized.16−20 However, the improvement
of the aqueous solubility was often accompanied by a
signiﬁcant decrease in cytotoxicity. In this study, the
attachment of N-substituted morpholine moiety at the TSC
backbone resulted in a simultaneous improvement of aqueous
solubility and cytotoxicity (up to ∼50 times in comparison
with triapine). To ensure the selectivity of novel TSCs toward
cancer cells over healthy cells, their cytotoxicity against A2780
cancer cells and noncancerous HEK293 cells was compared. It
was shown that new compounds were 2−5-fold more toxic
toward cancer cells than healthy cells (Tables 1 and 2),
whereas triapine was more toxic toward noncancerous cells,
which is in agreement with its known high toxicity. The
coordination of TSCs to Cu(II) resulted in Cu(II)−TSC
complexes with similar or improved antiproliferative activity. In
general, when TSCs are coordinated to Cu(II), an increase in
cytotoxicity is observed;17,18,53 however, Cu(II)−triapine
complex was shown to be signiﬁcantly less cytotoxic than
triapine itself.27 The activity of the Cu(II) complexes 1−6 was
in a good correlation with their lipophilicity, cellular
accumulation, and their electrochemical redox potentials
(Tables S6 and 2). Interestingly, metal-free TSCs exhibited
only low antibacterial properties against S. aureus, whereas
Cu(II)−TSC complexes revealed signiﬁcant antibacterial
activity similar to that of the commonly used antibiotic CPX
(Table 3). These results indicate that coordination of TSCs to
Cu(II) improved their therapeutic potential. It should be
noted that the replacement of N,N,S- with N,N,N-chelating
moiety in 6 resulted in a drop of cytotoxicity and antibacterial
activity, which is in agreement with the previously reported
data.20
The antiproliferative activity of triapine and other TSC
proligands is often related to their Fe-chelating properties.54
To sustain their high proliferation rate, cancer cells rely on
increased uptake of Fe from Fe-transporting proteins;
therefore, Fe chelation is a valuable therapeutic strategy for
cancer treatment. On the basis of UV−vis and ESI-MS
experiments, it was demonstrated that irrespective of metal-to-
ligand ratio, proligands HL2 and HL5 readily reacted with
Fe(III) to form [FeIII(L2)2]
+ and [FeIII(L5)2]
+ species, which
could be reduced to Fe(II) bis-ligand complexes by the
reducing agent DTT. These results indicate that morpholine−
TSC hybrids, investigated in this study, may act as Fe
chelators. Additionally, spectroelectrochemical experiments
revealed that under reducing conditions, the Cu(II)−TSC
complexes could undergo reversible reduction to Cu(I)
species, with simultaneous release of proligands, suggesting
that these complexes may act as Fe chelators, also in cancer
cells. In addition, the presence of the Cu(II) ion in the cells
may lead to the production of ROS in vivo because of Cu(II)/
Cu(I) redox cycling.55
It is well known that one of the mechanisms contributing to
the cytotoxic eﬀects of Fe chelators is inhibition of the RNR
enzyme, which is highly expressed in cancer cells, and essential
for their DNA synthesis. The mechanism of RNR inhibition by
triapine has been extensively studied by several research
groups.41,46,47,51,56 It has been proposed that triapine interferes
with the assembly of the diﬀeric-tyrosyl radical cofactor in R2,
necessary for the catalytic activity of RNR.46,56 Moreover, it
has been shown that the presence of Fe is required for eﬀective
R2 inhibition,44,45 and that it is actually the Fe(II)−triapine
species that is responsible for the R2-speciﬁc RNR inhibitory
eﬀect of triapine.41,46,47,51,58 The Fe(II)−triapine complex may
be formed by chelation of Fe from the diﬀeric cofactor in R2 in
vitro41,44 and/or from intracellular iron pools in vivo.46,56 The
potent inhibition of human47 and mouse41 R2 RNR in vitro by
catalytic amounts of Fe(II)−triapine has been proposed to
involve ROS. Namely, ROS had been spin-trapped and
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detected by EPR spectroscopy, in the aerobic reaction between
human R2 RNR and Fe(II)−triapine, which had implicated
that O2 is important in tyrosyl radical destruction and that
ROS may ultimately be responsible for the pharmacologic
eﬀects of triapine in vivo.47 In another study of time-dependent
tyrosyl radical reduction in mouse R2 by triapine and its Zn,
Ga, Cu, and Fe complexes, the requirement of O2 in R2
inhibition was also suggested.41 This was based on the
observation that substoichiometric amounts of Fe(III)−
triapine relative to R2 (protein-to-complex mole ratio, 5:1)
reduced only 20% tyrosyl radical in anaerobic conditions,
compared with 100% in aerobic conditions. However, more
recently, in a diﬀerent experimental setup, namely, in the
presence of a 10-fold excess of Fe(II)−triapine over R2
protein, the role of ROS (and O2) in human R2 inhibition was
excluded.51 This study showed that the principle mechanism of
human R2 RNR inhibition by triapine, based on kinetic
measurements of tyrosyl radical, and 55Fe loss, is direct radical
quenching, in an iron-loaded protein. Furthermore, it implied
that Fe(II)−triapine can rapidly reduce the tyrosyl radical,
while leaving the protein in the met-state.
To investigate if R2 RNR could be the potential
biomolecular target for the novel morpholine−TSC hybrids,
as well as their Cu(II) complexes, molecular docking studies,
as well as R2 RNR tyrosyl radical reduction kinetic
experiments, were performed. It has been suggested that the
eﬃciency of R2 inhibition is likely to depend on the access of
the inhibitors to the diﬀeric center of R2;41,47 therefore, we
estimated the likelihood of the binding of TSC proligands
HL1−HL6 and their corresponding Cu(II) complexes 1−6 to
the surface of the R2 protein. It was demonstrated that new
TSCs and their Cu(II) complexes were deeply embedded into
the pocket of the R2 protein and exhibited hydrogen bonding
patterns similar to triapine (Figure 7). On the basis of the
results of the molecular docking studies suggesting plausible
binding to the mouse R2 protein, the time-dependent tyrosyl
radical reduction in the mouse R2 protein upon incubation
with the most cytotoxic complexes, 2 and 5, and the
corresponding proligands HL2 and HL5, at a 1:1 protein-to-
compound ratio, was measured by EPR spectroscopy. Only in
the presence of DTT (which can reduce Fe(III) to Fe(II) in
the R2 diﬀeric cofactor),40 HL2 and HL5 caused 50% tyrosyl
radical reduction (Figure S15a). These results show that R2
inactivation by HL2 and HL5 is not as eﬃcient as with triapine,
which causes 100% tyrosyl radical loss in mouse R2 after 5 min
(in the same experimental conditions).41 The most plausible
explanation for this observation is that diﬀerent mechanisms
are likely to be involved in R2 inhibition by HL2, HL5, and
triapine. The R2 inhibitory activity of the corresponding
Cu(II) complexes 2 and 5 was found to be similar to that of
the proligands (Figure S15a). This is likely due to the fact that
in the presence of DTT, the reduction of Cu(II) to Cu(I) leads
to the release of the proligands, which is in agreement with the
results of spectroelectrochemical experiments (vide supra).
Because the UV−vis, and ESI-MS experiments showed that
HL2 and HL5 act as tridentate ligands, and form stable
Fe(II)L2 complexes (Figure S15c,d and S16), it is possible to
propose that the mechanism of R2 inhibition by the TSC
proligands involves Fe chelation from the diﬀeric cofactor. On
the basis of the extent of tyrosyl radical reduction, it is
tempting to speculate that the subsequently formed Fe(II)
complexes are not potent inhibitors like the Fe(II)−triapine
complex. However, as this was not the aim of this paper, it is
reasonable to refrain from any conclusions prior to the detailed
mechanistic studies of mouse, human, and p53 R2 RNR
inhibition by the morpholine−TSC hybrids. Moreover, a
separate study should be dedicated only to the comparison of
the inhibitory potentials of selected TSCs, as well as their
Fe(II) complexes, to comprehensively understand the
structure−activity relationships, which in turn may explain
the mechanism of R2 RNR inhibition. Finally, even though R2
inhibition can be partially attributed to the marked anticancer
activity of 2 and 5, other biomolecular targets are likely to be
involved (Figure 10).
Fe homeostasis is an intrinsically complex process; hence, Fe
sequestration results in the alteration of various biomolecular
pathways. Besides RNR, Fe depletion aﬀects multiple
molecular targets including those regulating the cell cycle.57
It has been reported that the expression of cyclin D1, which
ensures the progression through the G1/S phase, was strongly
dependent on the cellular Fe status.58 It is believed that in Fe-
depleted conditions, down-regulation of cyclin D1 prevents
cells from entering the S phase, where Fe is needed for the
activity of the RNR enzyme and DNA synthesis.59 Fe chelation
by TSCs often results in the down-regulation of cyclin D1 and
subsequent cell cycle arrest at the G1/S phase.
60,61 As expected,
complex 2 was shown to induce strong dose-dependent down-
regulation of cyclin D1, whereas the protein expression of
cyclin B1, which is responsible for G2/M progression,
remained unchanged. To further investigate the potential
biomolecular targets of Fe-chelating compounds of interest, we
studied the phosphorylation of ERK protein, which belongs to
the MAPK family. The MAP kinases occupy the central
position in cell growth and apoptosis, and each MAP kinase
member plays a diﬀerent role in cellular responses.62 It was
reported that some Fe chelators induced cancer cell death
associated with the activation of p38 MAPK and ERK.63
Moreover, the MAPK-mediated cell death was characterized by
the decreased expression of cyclin D1.64 Complex 2, as well as
the corresponding proligand HL2, caused dose-dependent
phosphorylation of ERK in line with its activation, suggesting
Figure 10. Proposed molecular mechanism of cytotoxicity of 2.
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that MAPK pathway might be a potential mediator of the cell
death, induced by this complex.
Recently, it was discovered that chelation and depletion of
intracellular Fe leads to the activation of certain ER stress-
response proteins.65,66 Previously, several TSCs and their
Cu(II) complexes were reported to induce ER stress,
characterized by unfolded protein response (UPR) activa-
tion,67,68 ER expansion, and release of intracellular calcium.69
Because under reducing conditions, the TSCs and their Cu(II)
complexes demonstrated formation of Fe(II)−TSC complexes,
it may be suggested that they could possibly induce
sequestration of cellular Fe resulting in the ER stress. It occurs
due to the accumulation of misfolded and/or unfolded
proteins in ER, resulting in the disruption of cellular
homeostasis. To overcome stress, cells activate a rescue
program known as UPR, which operates via several signaling
pathways, namely, ATF6, PERK, and IRE1α. However, in case
of severe ER stress, the pro-survival program is switched oﬀ
and pro-apoptotic signaling takes place, characterized by the
enhanced expression of CHOP protein. Complex 2 was shown
to induce dose-dependent increase in the expression of IRE1α
and CHOP proteins, indicating the induction of UPR signaling
as a result of ER stress. Cell treatment with 2 resulted in a
concentration-dependent decrease of BiP/GRP78 protein
marker. The ER chaperon BiP/GRP78 plays a central role in
the survival machinery and its overexpression is associated with
tumor progression and metastases.70 The inhibition of BiP/
GRP78 indicates severe ER stress, resulting in the suppression
of pro-survival chaperones. The antibacterial properties of
novel Cu(II)−TSC complexes can be also related to ER stress
induction because it was recently demonstrated in in vitro and
in vivo experiments that chemical modulation of ER stress
might result in the overload of its machinery that can be
eﬀective in elimination of bacterial infection.71 Additionally, it
was reported that eﬃcient killing of methicillin-resistant S.
aureus was dependent on the induction of IRE1α UPR
pathway and required sustained generation of ROS.72 On the
basis of the observations that 2, but not proligand HL2,
induced antioxidant defence in cancer cells characterized by
NRF2 induction, it may be speculated that the ability of 2, but
not proligand HL2, to induce oxidative and ER stress, may be
related to the beneﬁcial antibacterial activity of Cu(II)−TSC
complexes over metal-free TSCs. However, it is not clear yet
why new complexes 1−6 did not inhibit the growth of P.
aeruginosa and their mechanism of action should be
investigated in more detail.
To cope with the severe perturbations imposed by drug
treatment, cancer cells develop adaptive responses to provide
them with survival advantage. However, TSCs and their Cu(II)
complexes signiﬁcantly disturbed cellular life-death balance
toward cell death, resulting in the induction of apoptosis. Both
proligand HL2 and complex 2 were demonstrated to induce
apoptosis characterized by PARP cleavage, decreased ex-
pression of XIAP, and increased PS translocation. It should be
noted that XIAP is a determining factor of cisplatin
chemoresistance in ovarian cancer cells, as it eﬀectively
suppresses apoptosis via caspase-3 and caspase-7 inhibition.73
Therefore, the ability of 2 to decrease XIAP expression is
highly important and to the best of our knowledge has not
been previously reported for TSCs and metal thiosemicarbaz-
onates, with the exception of triapine.74 Some TSCs and their
respective Cu(II) complexes have been reported to simulta-
neously induce various types of cell death including
apoptosis,75,76 autophagy63,77 and methuosis, which is a very
special form of nonapoptotic cell death involving massive
cytoplasmic vacuolization.78 Therefore, induction of other
forms of cell death by new TSCs and their Cu(II) complexes
presented in this study cannot be excluded. The results show
that the attachment of the morpholine moiety at the TSC
backbone and the subsequent coordination to Cu(II) resulted
in new drug candidates, likely with better therapeutic proﬁle
than triapine and a promising potential for further clinical
development.
4. CONCLUSIONS
One of the reasons hindering the clinical development of
Cu(II) TSC complexes is their low aqueous solubility. The
decoration of the TSC backbone with functional groups that
increase the aqueous solubility and bioavailability often results
in a signiﬁcant decrease of the compound activity. In this work,
attachment of a morpholine moiety to 2-formylpyridine
(iso)TSC in position 5 of 2-formylpyridine moiety yielded
new water-soluble TSC−morpholine hybrids and their Cu(II)
complexes, which demonstrated high antiproliferative activity
against cisplatin-sensitive and cisplatin-resistant ovarian
carcinoma cells, in a nanomolar to submicromolar concen-
tration range. Suﬃcient aqueous solubility of the new
compounds enabled the study of their solution behavior and
electrochemical properties under conditions similar to the
intracellular environment. Solution speciation studies of 1
revealed that the dissociation of the complex does not occur at
the physiological pH, even at micromolar concentrations,
indicating its high stability in aqueous media. However, under
reducing conditions associated with the cancer cell environ-
ment, the reversible reduction of Cu(II) with subsequent
release of the proligand within the biologically accessible
electrochemical window is plausible. Because the R2 RNR
protein is believed to be one of the biomolecular targets of
TSCs, and the fact that the proligands form 2:1 complexes with
Fe(II), the chelation of Fe(II) from R2 was expected. The
Cu(II)−TSCs and their corresponding proligands showed only
moderate tyrosyl radical reduction in mouse R2. Therefore, the
marked anticancer activity of the compounds investigated in
this work was not solely related to their RNR inhibitory
potential but also to the induction of apoptosis as a result of
ER stress, MAPK activation, and cell cycle perturbations.
Studies of the mechanisms controlling cellular accumulation of
the lead drug 2 have shown that it accumulates in cancer cells
as a result of passive and/or facilitated diﬀusion. Finally, it was
discovered that coordination of TSC ligands to Cu(II) resulted
in a signiﬁcant enhancement of their antibacterial properties
against S. aureus. The combination of excellent antiproliferative
and antibacterial activity, as well as water-solubility, is a sound
basis for further development of this class of Cu(II)
thiosemicarbazonates as dual pharmaceutical agents.
5. EXPERIMENTAL SECTION
5.1. Chemicals. 2,5-Pyridinecarboxylic acid was received from
Alfa Aesar. EDTA, KOH, and 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid (HEPES) were purchased from Sigma-Aldrich in
puriss quality. KCl, CuCl2, hydrochloric acid, and n-octanol are
products of Molar Chemicals. CuCl2 stock solution was prepared
from anhydrous CuCl2 and water, and its exact concentration was
determined by complexometry through the EDTA complex. All
solvents were of analytical grade and used without further puriﬁcation.
Milli-Q water was used for sample preparation. The synthesis of the 5-
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methylmorpholine-pyridine-2-carboxaldehyde H (Scheme 1) is
described in detail in the Supporting Information. Chemical grade
cisplatin (1 mg/mL) was purchased from Hospira Pty Ltd
(Melbourne, Australia). IGEPAL CA-630, DL-dithiothreitol (DTT),
tetramethylethylenediamine, sodium deoxycholate, nonfat dried milk
bovine, TWEEN 20, ponceau S, and PI were purchased from Sigma-
Aldrich (St Louis, MO, USA). Thiazolyl blue tetrazolium bromide
(MTT) was purchased from Alfa Aesar, while Tris was purchased
from Vivantis Technologies. Glycine, Hyclone Trypsin Protease 2.5%
(10×) solution, RPMI 1640, Dulbecco’s modiﬁed Eagle’s medium
(DMEM) medium, fetal bovine serum (FBS), bovine serum albumin
(BSA), HBSS and Pierce Protease, and Phosphatase Inhibitor Mini
Tablets were from Thermo Fisher Scientiﬁc. Hyclone Dulbecco’s
phosphate-buﬀered saline (10×) was received from GE Healthcare
Life Sciences. Biorad protein assay dye reagent concentrate, 30%
acrylamide/bis solution, 5× Laemmli sample buﬀer, and nitrocellulose
membrane (0.2 μm) were from Bio-Rad Laboratories. Luminata
Classico and Crescendo Western HRP substrate were purchased from
Merck Millipore Corporation. Milli-Q-grade puriﬁed water was
obtained from a Milli-Q UV puriﬁcation system (Sartorius Stedim
Biotech S.A., Aubagne Cedex, France). All antibodies were from Cell
Signaling Technologies (Beverly, MA, USA). Nitric acid (65 to 71%,
TraceSELECT Ultra) for ICP−MS analysis and nBu4NPF6 for cyclic
voltammetry experiments were obtained from Fluka (Sigma Aldrich)
and used without further puriﬁcation. Cu and In standards for ICP−
MS measurements were obtained from CPI international (Amster-
dam, The Netherlands). Cycloheximide, oligomycin, and annexin V-
FITC apoptosis detection reagent (500×) were purchased from
Abcam (Cambridge, UK).
5.2. Synthesis of Proligands. The yields, mp, and analytical data
for HL1−HL6 and 1−6 are presented in Tables S9 and S10. The
experimental CHNS contents were within ±0.4 with those calculated,
providing evidence for ≥95% purity.
5.2.1. 5-(Morpholinomethyl)pyridine-2-carboxaldehyde Thiose-
micarbazone (HL1). 5-Morpholinomethyl-pyridine-2-carboxaldehyde
(0.29 g, 1.41 mmol), thiosemicarbazide (0.13 g, 1.41 mmol), and
EtOH (5 mL) were mixed in a 25 mL Schlenk tube. The reaction
mixture was stirred at 78 °C overnight. The next day, the reaction
mixture was cooled to room temperature and stored at 4 °C for 4 h.
The white crystalline precipitate was ﬁltered oﬀ, washed with cold
EtOH, and dried in vacuo. Yield: 0.34 g. 1H NMR 500 MHz (DMSO-
d6, δ, ppm):
1H NMR (500 MHz, DMSO): δ 11.62 (s, 1H, NH16),
8.48 (d, J = 1.3 Hz, 1H, H5), 8.34 (s, 1H, NH19), 8.24 (d, J = 8.1 Hz,
1H, H2), 8.15 (s, 1H, NH19), 8.09 (s, 1H, H14), 7.74 (dd, J = 8.2, 1.7
Hz, 1H, H4), 3.59−3.54 (m, 4H, H10, H12), 3.51 (s, 2H, H7), 2.36 (s,
4H, H9, H13). 13C NMR (126 MHz, DMSO): δ 178.74 (Cq, C
17),
152.73 (Cq, C
2), 150.12 (CH, C6), 142.85 (CH, C14), 137.51 (CH,
C4), 134.23 (Cq, C
5), 120.23 (CH, C3), 66.57 (2CH2, C
10, C12), 59.74
(CH2, C
7), 53.49 (2CH2, C
9, C13). IR (ATR, selected bands, νm̃ax):
1612, 1527, 1468, 1400, 1339, 1274, 1102, 1004, 938, 859, 626 cm−1.
5.2.2. 5-(Morpholinomethyl)pyridine-2-carboxaldehyde 4,4-Di-
methyl-3-thiosemicarbazone (HL2). 5-(Morpholinomethyl)pyridine-
2-carboxaldehyde (0.29 g, 1.41 mmol) and 4,4-dimethyl-3-thiosemi-
carbazide (0.17 g, 1.41 mmol) were dissolved in EtOH (5 mL) and
stirred in a Schlenk tube at 78 °C for 2 h until the solution became
clear. The reaction mixture was left to stand at 4 °C for 6 h. The
yellow crystalline precipitate was ﬁltered oﬀ, washed with cold EtOH,
and dried in vacuo. Yield: 0.25 g. 1H NMR (500 MHz, DMSO): δ
15.08 (s, 1H, NH16), 8.71 (s, 1H, H3), 8.49 (s, 1H, H6), 8.23 (d, 1H,
H14), 7.76 (dd, J = 13.9, 8.1 Hz, 1H, H4), 3.59 (s, 4H, H10, H12), 3.52
(s, 2H, H7), 3.38 (s, 4H, H20, H21), 2.37 (s, 4H, H9, H13).·13C NMR
(126 MHz, DMSO): δ 180.02 (Cq, C
17), 153.06 (Cq, C
2), 150.27
(CH, C6), 148.84 (CH, C3), 144.29 (CH, C14), 137.75 (CH, C4),
134.06 (Cq, C
5), 66.61 (2CH2, C
10, C12), 59.77 (CH2, C
7), 53.53
(2CH2, C
9, C13), 42.72 (2CH3, C
20, C21). IR (ATR, selected bands,
νm̃ax): 1497, 1443, 1362, 1303, 1209, 1158, 1108, 1064, 1003, 901,
862, 716, 627 cm−1.
5.2.3. 5-(Morpholinomethyl)pyridine-2-Carboxaldehyde N-Pyr-
rolidinylthiosemicarbazone (HL3). 5-(Morpholinomethyl)pyridine-2-
carboxaldehyde (0.29 g, 1.41 mmol) and N-pyrrolidine-3-thiosemi-
carbazide (0.20 g, 1.41 mmol) were dissolved in EtOH (5 mL) and
stirred in a Schlenk tube at 78 °C for 2 h until the solution became
clear. The mixture was left to stand at 4 °C for 12 h. The yellow
crystalline precipitate was ﬁltered oﬀ, washed with cold EtOH, and
dried in vacuo. Yield: 0.36 g. 1H NMR (500 MHz, DMSO): δ 11.23
(s, 1H, NH16), 8.49 (d, J = 1.4 Hz, 1H, H3), 8.20 (s, 1H, H6), 8.01
(dd, J = 8.0, 2.1 Hz, 4H, H21, H22), 7.84 (s, 1H, H14), 7.77 (d, J = 1.9
Hz, 1H, H4), 3.76 (s, 4H, H20, H23), 3.59 (dd, J = 8.1, 5.3 Hz, 4H, H9,
H13), 3.52 (s, 2H, H7), 2.42−2.32 (m, 4H, H10, H12). 13C NMR (126
MHz, DMSO): δ 177.02 (Cq, C
17), 153.11 (Cq, C
2), 150.17 (CH,
C6), 149.02 (CH, C3), 143.48 (CH, C14), 139.44, (2CH2, C
21, C22),
138.08 (CH, C16), 134.05 (Cq, C
5), 119.43 (CH, C3), 66.62 (2CH2,
C9, C13), 59.91 (CH2, C
7), 53.53 (2CH2, C
20, C23), 40.00 (2CH2, C
10,
C12, overlapped with residual DMSO signal). IR (ATR, selected
bands, νm̃ax): 1585, 1529, 1419, 1347, 1287, 1108, 1001, 855, 796, 741
cm−1.
5.2.4. 5-(Morpholinomethyl)pyridine-2-carboxaldehyde N-Mor-
pholinylthiosemicarbazone (HL4). 5-(Morpholinomethyl)pyridine-2-
carboxaldehyde (0.29 g, 1.41 mmol) and N-morpholinyl-3-thiosemi-
carbazide (0.23 g, 1.41 mmol) were dissolved in EtOH (5 mL) and
stirred in a Shlenk tube at 78 °C for 2.5 h until the solution became
clear. Light-yellow crystals formed within 3 weeks at 4 °C after
concentration of the reaction mixture. These were ﬁltered oﬀ, washed
with cold EtOH, and dried in vacuo. Yield: 0.12 g. 1H NMR (500
MHz, DMSO): δ 11.43 (s, 1H, NH16), 8.50 (d, J = 1.3 Hz, 1H, H6),
8.18 (s, 1H, H14), 7.83 (d, J = 8.1 Hz, 1H, H4), 7.78 (dd, J = 8.2, 1.9
Hz, 1H, H3), 3.98−3.91 (m, 4H, H20, H24), 3.72−3.66 (m, 4H, H21,
H23), 3.60−3.55 (m, 4H, H9, H13), 3.52 (s, 2H, H7), 2.36 (br s, 4H,
H10, H12). 13C NMR (126 MHz, DMSO): δ 181.27 (Cq, C
17), 152.75
(Cq, C
4), 150.33 (CH, C6), 144.44 (CH, C14), 137.83 (CH, C3),
134.27 (CH, C2), 119.60 (Cq, C
4), 66.60 (2CH2, C
21, C23), 66.48
(CH2, C
7), 59.73 (2CH2, C
9, C13).
5.2.5. 5-(Morpholinomethyl)pyridine-2-carboxaldehyde 4-Phe-
nylthiosemicarbazone (HL5). 5-(Morpholinomethyl)pyridine-2-car-
boxaldehyde (0.29 g, 1.41 mmol) and 4-phenyl-3-thiosemicarbazide
(0.24 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a
Schlenk tube at 78 °C for 3 h until the solution became clear. Then,
the reaction mixture was allowed to stand at 4 °C for 12 h. The yellow
crystalline precipitate was ﬁltered oﬀ, washed with cold EtOH, and
dried in vacuo. Yield: 0.32 g. 1H NMR (500 MHz, DMSO): δ 12.02
(s, 1H, NH16), 10.24 (s, 1H, NH18), 8.52 (s, 1H, H6), 8.41 (d, J = 8.1
Hz, 1H, H3), 8.21 (s, 1H, H14), 7.78 (d, J = 10.1 Hz, 1H, H4), 7.56 (d,
J = 8.6 Hz, 2H, H21, H25), 7.40 (t, J = 7.9 Hz, 2H, H22, H24), 7.24 (t, J
= 7.4 Hz, 1H, H23), 3.59 (s, 4H, H10, H12), 3.54 (s, 2H, H7), 2.38 (s,
4H, H9, H13)·13C NMR (126 MHz, DMSO) δ 176.84 (Cq, C
17),
152.62 (Cq, C
2), 150.25 (CH, C6), 143.45 (Cq, C
14), 139.44 (Cq,
C20), 137.51 (CH, C4), 134.46 (Cq, C
5), 128.59 (2CH, C22, C24),
126.56 (2CH, C21, C25), 120.68 (CH, C3), 66.62 (2CH2, C
10, C12),
53.54 (2CH2, C
9, C13), 40.00 (CH2, C
7). IR (ATR, selected bands,
ν ̃max): 1592, 1505, 1466, 1338, 1291, 1188, 1105, 1060, 1000, 944,
909, 863, 791, 751, 689, 634 cm−1.
5.2.6. 5-(Morpholinomethyl)pyridine-2-carboxaldehyde S-Meth-
y l i sothiosemicarbazone (HL6 ) . To a solut ion of 5-
(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol)
in EtOH (6 mL) was added a solution of S-methylisothiosemicarba-
zide hydroiodide (0.33 g, 1.41 mmol) in water (2 mL). Then, the
reaction mixture was heated to 60 °C and a solution of NaHCO3
(0.118 g, 1.41 mmol) in water (4 mL) was added dropwise. When
bubbles of CO2 disappeared, the mixture was allowed to cool to room
temperature. The solvent was removed under reduced pressure and
the residue dissolved in water. The product was extracted with
chloroform. After removal of the solvent, the residue was dissolved in
a small amount of EtOH and allowed to stand at −20 °C overnight.
Light-brown crystalline product was obtained the next day. Yield: 0.14
g. 1H NMR (500 MHz, DMSO): δ 8.49 (d, J = 1.4 Hz, 1H, H4), 8.21
(d, J = 8.1 Hz, 1H, H14), 8.17 (s, 1H, H6), 7.84 (d, J = 8.1 Hz, 1H,
H3), 7.16 (s, 2H, H18), 3.60−3.55 (m, 8H, H9, H13), 3.51 (s, 2H, H7),
2.40 (br s, 3H, H20), 2.36 (d, J = 6.0 Hz, 8H, H10, H12). 13C NMR
(126 MHz, DMSO) δ 164.19 (Cq, C
17), 154.02 (Cq, C
5), 151.84
(CH, C6), 150.12 (CH, C4), 137.35 (CH, C3), 133.89, (C, C2),
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120.68 (CH, C14), 66.61 (2CH2, C
9, C13), 59.84 (CH2, C
7), 53.53
(2CH2, C
10, C12), 12.52 (CH3, C
20). IR (ATR, selected bands, νm̃ax):
1600, 1497, 1472, 1335, 1290, 1111, 1069, 1015, 931, 870, 790, 752,
714, 626 cm−1.
5.3. Synthesis of Cu(II) Complexes. 5.3.1. [Cu(L1)Cl] (1). To
HL1 (100 mg, 0.36 mmol) in MeOH (20 mL) was added
triethylamine (50 μL, 0.36 mmol) and then CuCl2·2H2O (60 mg,
0.36 mmol) in MeOH (5 mL) at 60 °C. The solution was stirred for 5
min and left to stand at room temperature overnight. The precipitate
formed was ﬁltered oﬀ, washed with cold EtOH, and dried in air.
Yield: 123 mg. IR (ATR, selected bands, ν ̃max): 1631, 1426, 1310,
1158, 1107, 1060, 907, 722, 688 cm−1.
5.3.2. [Cu(L2)Cl] (2). To HL2 (100 mg, 0.32 mmol) in MeOH (20
mL) was added triethylamine (44.5 μL, 0.32 mmol) and then CuCl2·
2H2O (54 mg, 0.32 mmol) in MeOH (5 mL) at 60 °C. The solution
was stirred for 5 min and left to stand at room temperature overnight.
The precipitate formed was ﬁltered oﬀ, washed with cold EtOH, and
dried in air. Yield: 104 mg. IR (ATR, selected bands, νm̃ax): 1505,
1372, 1310, 1252, 1111, 1000, 913, 872, 749, 626 cm−1.
5.3.3. [Cu(L3)Cl] (3). To HL3 (100 mg, 0.3 mmol) in MeOH (20
mL) was added triethylamine (42 μL, 0.28 mmol) and then CuCl2·
2H2O (50 mg, 0.3 mmol) in MeOH (5 mL) at 60 °C. The solution
was stirred for 5 min and left to stand at room temperature overnight.
The precipitate formed was ﬁltered oﬀ, washed with cold EtOH, and
dried in air. Yield: 74 mg. IR (ATR, selected bands, ν ̃max): 1444, 1375,
1281, 1242, 1111, 1004, 913, 885, 623 cm−1.
5.3.4. [Cu(L4)Cl] (4). To HL4 (50 mg, 0.28 mmol) in MeOH (20
mL) was added triethylamine (20 μL, 0.28 mmol) and then CuCl2·
2H2O (25 mg, 0.28 mmol) in MeOH (5 mL) at 60 °C. The solution
was stirred for 5 min and left to stand at room temperature overnight.
The precipitate formed was ﬁltered oﬀ, washed with cold EtOH, and
dried in air. Yield: 22 mg. IR (ATR, selected bands, ν ̃max): 1465, 1429,
1381, 1313, 1265, 1229, 1109, 1028, 932, 888, 860 cm−1.
5.3.5. [Cu(L5)Cl] (5). To HL5 (100 mg, 0.28 mmol) in MeOH (20
mL) was added triethylamine (39 μL, 0.28 mmol) and then CuCl2·
2H2O (47 mg, 0.82 mmol) in MeOH (5 mL) on heating. The
solution was stirred for 5 min and left to stand at room temperature
overnight. The precipitate formed was ﬁltered oﬀ, washed with cold
EtOH, and dried in air. Yield: 67 mg. IR (ATR, selected bands, νm̃ax):
1600, 1550, 1493, 1417, 1182, 1111, 1000, 899, 863, 799, 752, 691
cm−1.
5.3.6. [Cu(L6)Cl] (6). To HL6 (100 mg, 0.34 mmol) in MeOH (20
mL) was added triethylamine (47 μL, 0.34 mmol). Then, the reaction
was heated to 40 °C and CuCl2·2H2O (58 mg, 0.34 mmol) in MeOH
(5 mL) was added. The solution was stirred for 5 min at 50 °C and
left to stand at −20 °C overnight. The precipitate formed was ﬁltered
oﬀ, washed with ethanol, ether, and dried in air. Yield: 75 mg. IR
(ATR, selected bands, νm̃ax): 1599, 1491, 1431, 1320, 1115, 1035,
1004, 973, 911, 796, 724 cm−1.
5.4. Solution Equilibrium Studies in Aqueous Phase.
5.4.1. pH-Potentiometric Measurements. These measurements
were performed as described previously.16 The initial volume of the
samples was 10.0 mL. The proligand concentration was 1 mM and
metal ion-to-ligand ratios of 1:1 to 1:3 were used. The exact
concentration of the proligand stock solutions together with the
proton dissociation constants were determined by pH-potentiometric
titrations with the use of the computer program HYPERQUAD.79
HYPERQUAD was also utilized to establish the stoichiometry of the
complexes and to calculate the stability constants (log β(MpLqHr)).
β(MpLqHr) is deﬁned for the general equilibrium pM + qL + rH ⇌
MpLqHr as β(MpLqHr) = [MpLqHr]/[M]
p[L]q[H]r, where M denotes
the metal ion and L denotes the completely deprotonated ligand. The
uncertainties (SDs) of the equilibrium constants are shown in
parentheses for the species determined in the present work.
5.5. Instrumentation. ICP−Optical Emission Spectroscopy
(OES) determination of the Cu content was performed in Chemical,
Molecular and Analysis Centre, National University of Singapore with
Optima ICP−OES (PerkinElmer, Watham, MA, USA). The
absorbance of thiazolyl blue tetrazolium bromide (MTT) was
measured by synergy H1 hybrid multimode microplate reader (Bio-
Tek, Winoosky, VT, USA). Cu and Re contents in cells were
determined by Agilent 7700 Series ICP−MS (Agilent Technologies,
Santa Clara, CA, USA). Flow cytometry was performed on BD
LSRFortessa Cell Analyzer (BD Biosciences, Franklin Lakes, NJ,
USA). Western blot images were generated from G:Box (Syngene,
Cambride, UK). The UV−vis spectrophotometric measurements
were performed on a Hewlett Packard 8452A diode array
spectrophotometer and a Thermo Scientiﬁc Evolution 220
spectrophotometer. CW-EPR spectra were recorded with a BRUKER
EleXsys E500 spectrometer. In situ ultraviolet−visible−near-infrared
(UV−vis−NIR) spectroelectrochemical measurements were per-
formed on a spectrometer (Avantes, Model AvaSpec-2048x14-USB2.
5.6. UV−Vis Spectrophotometric, 1H NMR, EPR, and
Lipophilicity Measurements. UV−vis spectra were recorded in
the ranges 200−800 and 450−1050 nm, respectively. The path length
was 0.5, 1, or 2 cm. Stability constants of the complexes and the molar
absorbance spectra of the individual species were calculated with the
computer program PSEQUAD.80 The spectrophotometric titrations
were performed on samples containing the proligand with or without
Cu(II) ions and the concentration of the proligand was 120 μM to 1.4
mM. The metal-to-proligand ratios were 1:1 and 1:2 in the pH range
from 1.0 to 11.5 at 25.0 ± 0.1 °C at an ionic strength of 0.10 M
(KCl). pH values in the range 1.0−2.0 were calculated from the
strong acid and strong base content. The conditional stability constant
of [CuL] at pH 6.0 (50 mM MES) for 1 was determined from
competition titrations of the Cu(II) complex of EDTA with the
proligand HL1. Samples contained 34 μM Cu(II) ion and 34 μM
HL1, and the concentration of the EDTA was varied in the range of
0−83 μM. Absorbance data were recorded after 0.5 h incubation. 1H
NMR studies for HL1 were carried out on a Bruker Avance III HD
Ascend 500 Plus instrument in a 10% (v/v) D2O/H2O mixture at
ionic strength of 0.10 M (KCl). All CW-EPR spectra were recorded
with a BRUKER EleXsys E500 spectrometer (microwave frequency
9.85 GHz, microwave power 10 mW, modulation amplitude 5 G,
modulation frequency 100 kHz). The pH-dependent series of
isotropic EPR spectra were recorded in a circulating system, at
room temperature. A Heidolph Pumpdrive 5101 peristaltic pump was
used for circulating the solution from the titration pot through a
capillary tube into a Bruker ﬂat cell placed in the cavity of the
instrument. The titrations were carried out under a nitrogen
atmosphere. EPR spectra were recorded at 1.00 mM Cu(II) and
0.75 mM ligand concentration, and at 1.00 mM CuCl2 and 1.50 mM
ligand concentration, both between pH 1 and 11.5. The ionic strength
of 0.1 M was adjusted with KCl. Before the simulation of the room
temperature spectra, the measured spectra were corrected by
subtracting the spectra of aqua solution measured in the same
circulating system. The series of pH-dependent isotropic EPR spectra
recorded in the equimolar solution were simulated by the “two-
dimensional” method using the 2D_EPR program81 and EPR
parameters were computed as published previously.16,25 Distribution
coeﬃcients (D7.4) values of complexes 1−6 and HL1−HL6 were
determined by the traditional shake-ﬂask method in n-octanol/
buﬀered aqueous solution at pH 7.40 (20 mM HEPES, 0.10 M KCl)
at 25.0 ± 0.2 °C as described previously.82
5.7. Crystallographic Structure Determination. X-ray dif-
fraction quality single crystals of HL1, HL2, and HL4−HL6 were
obtained by recrystallization in ethanol, while 1 and 3−6 by slow
diﬀusion of diethyl ether into the DMF and methanolic solution of
the complexes, respectively. The measurements were performed on a
Bruker X8 APEX-II CCD (HL1, HL2, HL4, HL5, 1′, 3−6), Bruker D8
Venture (1), or Gemini (HL6) diﬀractometer. Single crystals were
positioned at 35, 35, 35, 35, and 55 mm from the detector, and 388,
1110, 946, 1108, and 2935 frames were measured, each for 40, 3, 60,
3, and 32 s over 0.5°, 0.5°, 0.5°, 0.5°, and 1.0° scan width for HL1,
HL2, and HL4−HL6, respectively. For Cu(II) complexes 1, 1′, 3−6
the single crystals were placed at 24, 35, 35, 33, 35, and 24 mm from
the detector, and 8088, 2692, 794, 1212, 1261, and 567 fames were
measured, each for 3, 2, 60, 60, 60, and 3 s over 0.6°, 0.5°, 0.5°, 0.5°,
0.4°, and 0.5° scan width, respectively. The data were processed using
SAINT or CrysAlis software.83,84 Crystal data, data collection
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parameters, and structure reﬁnement details are given in Tables S11
and S12. The structures were solved by direct methods and reﬁned by
full-matrix least-squares techniques. Non-H atoms were reﬁned with
anisotropic displacement parameters. H atoms were inserted in
calculated positions and reﬁned with a riding model. The morpholine
group and the N-piperidinyl unit in one of three crystallographically
independent molecules in the asymmetric unit were found to be
disordered over two positions with s.o.f. 0.5:0.5 and 0.6:0.4 in 3·
0.25MeOH. The morpholine moiety attached to pyridine unit in one
of the three crystallographically independent molecules of 4·
0.58MeOH was found to be disordered over two positions with
s.o.f. 0.7:0.3. In addition, one molecule of methanol was found
disordered over two positions with s.o.f. 0.75:0.25. The positional
parameters of disordered atoms were reﬁned by using PART, DFIX,
and SADI tools implemented in SHELX. The following computer
programs and hardware were used: structure solution, SHELXS-2014
and reﬁnement, SHELXL-2014;85 molecular diagrams, and ORTEP;86
computer, Intel CoreDuo. CCDC 1850567−1850577.
5.8. Electrochemistry and Spectroelectrochemistry. Cyclic
voltammetric experiments were performed as described previously.46
The cyclic voltammograms were measured in the cathodic region in
diﬀerent solvents (DMSO, methanol, DMSO/H2O). The analytical
purity grade LiClO4 (Sigma-Aldrich) and distilled and deionized
water were used for preparation of 1 mM aqueous solutions of the
investigated complexes 1−6. EPR spectra were recorded with the
EMX plus. In situ UV−vis−NIR spectroelectrochemical measure-
ments were performed on a spectrometer (Avantes, Model AvaSpec-
2048x14-USB2 in the spectroelectrochemical cell kit (AKSTCKIT3))
with the Pt-microstructured honeycomb working electrode, purchased
from Pine Research Instrumentation. The cell was positioned in the
CUV−UV Cuvette Holder (Ocean Optics) connected to the diode-
array UV−vis−NIR spectrometer by optical ﬁbers. UV−vis−NIR
spectra were processed using the AvaSoft 7.7 software package.
Halogen and deuterium lamps were used as light sources (Avantes,
Model AvaLight-DH-S-BAL). The in situ EPR spectroelectrochemical
experiments were carried out under an argon atmosphere in the EPR
ﬂat cell equipped with a large platinum mesh working electrode. The
freshly prepared solutions were carefully purged with argon and the
electrolytic cell was polarized in the galvanostatic mode directly in the
cylindrical EPR cavity TM-110 (ER 4103 TM), and the EPR spectra
were measured in situ.
5.9. Cell Lines and Culture Conditions. Human ovarian
carcinoma cells A2780 and A2780cisR and human embryonic kidney
HEK293 were obtained from ATCC. A2780 and A2780cisR cells
were cultured in RPMI 1640 medium containing 10% FBS. HEK293
were cultured in DMEM medium containing 10% FBS. All cells were
grown in tissue culture 25 cm2 ﬂasks (BD Biosciences, Singapore) at
37 °C in a humidiﬁed atmosphere of 95% air and 5% CO2. All drug
stock solutions were prepared in sterile water. The amount of Cu was
determined by ICP−OES. All compounds were soluble in water;
more speciﬁcally, the solubility of 1, 2, and 5 was moderate and did
not exceed 2 mM, whereas 3 was less soluble (0.3 mM) in water.
5.10. Inhibition of Cell Viability Assay. The cytotoxicity of the
compounds was determined by colorimetric microculture assay
(MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) as described previously.46
5.11. Cellular Accumulation. Cellular accumulation of 1−6 was
determined in A2780 cells. Cells were seeded into Cellstar 6-well
plates (Greiner Bio-one) at a density of 60 × 104 cells/well (2 mL per
well). After the cells were allowed to resume exponential growth for
24 h, they were exposed to 1−6 at 1 μM for 24 h at 37 °C. The cells
were washed twice with 1 mL of PBS and lysed with RIPA lysis buﬀer
for 5−10 min at 4 °C. The cell lysates were scraped from the wells
and transferred to separate 1.5 mL microtubes. The supernatant was
then collected after centrifugation (13 000 rpm, 4 °C for 15 min) and
total protein content of each sample was quantiﬁed via Bradford’s
assay. Cell lysates were transferred to 2 mL glass vials and then
digested with ultrapure 65% HNO3 at 100 °C for 24 h. The resulting
solution was diluted to 1 mL (2−4% v/v HNO3) with ultrapure Milli-
Q water. Cu content of each sample was quantiﬁed by ICP−MS. In
was used as an internal standard. Cu and In were measured at m/z 64
and m/z 115, respectively. Metal standards for calibration curve (0,
0.5, 1, 2, 5, 10, 20, and 40 ppb) were freshly prepared before each
measurement. All readings were made in triplicates in He mode. For
temperature-dependent cellular accumulation experiments, A2780
cells were seeded into 35 n 10 mm tissue culture plates at a density of
60 0 104 cells/plate. After the cells were allowed to resume
exponential growth for 24 h, they were exposed to 2 at 3 μM for
10, 30, 60, and 120 min at 37 and 4 °C. The subsequent analysis was
performed as described above. For energy-dependent experiments,
A2780 cells were seeded into 35 5 10 mm tissue culture plates at a
density of 1 0 106 cells/plate. After the cells were allowed to resume
exponential growth for 24 h, they were preincubated with oligomycin
(5 μM) for 1 or 4 h or with cycloheximide (100 μM) for 4 h and
further co-incubated with 3 μM of 2 at 37 °C. To induce total
starvation, after the cells were allowed to resume exponential growth
for 24 h, RPMI media was replaced with HBSS, and cells were
preincubated in HBSS for 1 h and further incubated with 3 μM of 2
for 1 h at 37 °C. The subsequent analysis was performed as described
above.
5.12. Western Blot Analysis. A2780 cells were seeded into
Cellstar 6-well plates (Greiner Bio-One) at a density of 60 × 104
cells/well (2 mL per well). After the cells were allowed to resume
exponential growth for 24 h, they were exposed to HL2 and 2 at
diﬀerent concentrations for 24 h. The experiment was performed
essentially as described previously.46 The membranes were blocked in
5% BSA (w/v) in TBST wash buﬀer for 1 h and subsequently
incubated with the appropriate primary antibodies in 5% BSA (w/v)
in TBST wash buﬀer (actin antibody) at 4 °C overnight. The
membranes were washed with a wash buﬀer three times for 5 min.
After incubation with horseradish peroxidase-conjugated secondary
antibodies (room temperature, 1.5 h), the membranes were washed
with a wash buﬀer four times for 5 min. Immune complexes were
detected with Luminata HRP substrates and analyzed using enhanced
chemiluminescence imaging. Actin was used as a loading control. The
following antibodies were used: NRF2 (sc13032) from Santa Cruz
Biotechnologies, ECL Antirabbit IgG (NA934 V), and ECL
Antimouse IgG (NA931) from GE Healthcare Life Sciences, cleaved
PARP (Asp214) (D64E10), PARP, CHOP (D46F1), BiP (C50B12),
IRE1α (14C10), β-actin (13E5), phospho-p44/p42 MAPK (Erk1/2)
(Thr202/Tyr204) (D13.14.4E), cyclin D1 (92G2), cyclin B1
(D5C10), and XIAP antibodies from Cell Signalling Technologies.
All antibodies were used at 1:500 dilutions except for actin (1:10
000), antimouse and antirabbit (1:5000).
5.13. Annexin V/PI Apoptosis Assay. A2780 cells were seeded
into Cellstar 12-well plates (Greiner Bio-One) at a density of 20 × 104
cells/well (1 mL per well). The cells were allowed to resume
exponential growth for 24 h and subsequently they were exposed to
HL2 and 2 at diﬀerent concentrations for 24 h. After the supernatant
solution was collected in 1.5 mL microtubes, the cells were washed
with 100 μL of trypsin, which was combined with the supernatant.
Subsequently, cells were trypsinized with 200 μL of trypsin for 5 min
at 37 °C, 5% CO2, washed with 200 μL of PBS, and combined with
the supernatant. The cells were centrifuged at 2.5 × 103 rpm for 5 min
and the pellets were washed once with PBS and resuspended in 500
μL of Annexin V binding buﬀer and stained with Annexin V-FITC
and PI reagents. The ﬂuorescence was immediately analyzed by ﬂow
cytometry. The resulting dot blots were acquired from 10 000 events
and quantiﬁed using Flowjo software (Flowjo LLC, Ashland, OR,
USA).
5.14. Tyrosyl Radical Reduction in Mouse R2 Ribonucleo-
tide Reductase Protein. The 9.4 GHz EPR spectra were recorded
at 30 K on a Bruker EleXsys II E540 EPR spectrometer with an
Oxford Instruments ESR900 helium cryostat, essentially as described
previously.51 The mouse R2 subunit was produced from Escherichia
coli carrying a mouse R2 cDNA plasmid. The protein was
reconstituted with Fe, resulting in the formation of the cluster with
0.38 tyrosyl radical/Fe per monomer, which is in agreement with the
literature.41
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5.15. Molecular Docking Calculations. The calculations were
performed as described previously.20 The center of the binding pocket
was deﬁned (x = 102.276, y = 87.568, z = 80.588) with 10 Å radius.
The basic amino acids lysine and arginine were deﬁned as protonated.
Furthermore, aspartic and glutamic acids were assumed to be
deprotonated. The GoldScore (GS),37 ChemScore (CS),88,89 Chem
Piecewise Linear Potential (ChemPLP),90 and Astex Statistical
Potential (ASP)87 scoring functions were implemented to validate
the predicted binding modes and relative energies of the ligands using
the GOLD v5.4 software suite. The parameter ﬁle for GS was
augmented for Cu according to Sciortino et al.38 The QikProp 4.691
and Marvin software package92 was used to calculate the molecular
descriptors of the compounds. The reliability of QikProp is
established for the molecular descriptors.93
5.16. Bacterial Strains and Antibacterial Activity. Wild-type
P. aeruginosa PAO1 strain CECT 4122 (ATCC 15692) and S. aureus
CECT 86 (ATCC 12600) were obtained from the Spanish Type
Culture Collection (CECT). All strains were routinely cultivated in
TSB medium (Sharlab, Spain) at 37 °C. MIC assays were determined
by the microdilution method using TSB broth following the method
described by the Clinical and Laboratory standards Institute.94 In
brief, compounds were diluted in a 96-well microtiter plate (tissue
culture-treated polystyrene; Costar 3595, Corning Inc., Corning, NY)
to a ﬁnal concentration ranging from 0.1 to 100 μg/mL. A 100 μL
aliquot of the bacterial suspension (around 5 × 105 cfu/mL) was
inoculated, incubated at 37 °C for 8 h at 150 rpm, and absorbance at
550 nm was read every 15 min in an Inﬁnity 200 Pro microplate
reader (Tecan). The MIC100 was determined as the lowest
concentration that completely inhibited bacterial growth and MIC50
in which bacterial growth was inhibited at 50%.
5.17. Bacterial Viability Test Analysis. Cultures of S. aureus and
P. aeruginosa were diluted in fresh TSB medium and grown overnight
to the beginning of exponential phase (A550 0.3), and diﬀerent
compounds were added. After 3 h of incubation at 37 °C in shaking
conditions, cells were harvested and stained using the LIVE/DEAD
BactLight Bacterial Viability Kit (Thermoﬁsher) for 30 min.
Fluorescent bacteria were visualized by a Nikon inverted ﬂuorescent
microscope ELIPSE Ti-S/L100 (Nikon) coupled with a DS-Qi2
Nikon camera.
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